APA (7th ed.) Citation

PR, P., F, T., JS, D., M, C., L, L., O, B., . . . A, N. (2024). Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns. Heliyon, 10(10), e30862. https://doi.org/10.1016/j.heliyon.2024.e30862

Chicago Style (17th ed.) Citation

PR, Petit, et al. "Further Preclinical Characterization of Molnupiravir Against SARS-CoV-2: Antiviral Activity Determinants and Viral Genome Alteration Patterns." Heliyon 10, no. 10 (2024): e30862. https://doi.org/10.1016/j.heliyon.2024.e30862.

MLA (9th ed.) Citation

PR, Petit, et al. "Further Preclinical Characterization of Molnupiravir Against SARS-CoV-2: Antiviral Activity Determinants and Viral Genome Alteration Patterns." Heliyon, vol. 10, no. 10, 2024, p. e30862, https://doi.org/10.1016/j.heliyon.2024.e30862.